979 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B N/A
Article Searches
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review http://www.zacks.com/stock/news/775823/roches-tecentriq-sbla-for-lung-cancer-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-775823 Feb 20, 2020 - Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.
What's in Store for Jounce (JNCE) This Earnings Season? http://www.zacks.com/stock/news/775281/whats-in-store-for-jounce-jnce-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-775281 Feb 20, 2020 - Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4? http://www.zacks.com/stock/news/773184/is-a-beat-in-the-cards-for-clovis-clvs-earnings-in-q4?cid=CS-ZC-FT-analyst_blog|earnings_preview-773184 Feb 19, 2020 - Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.
Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat http://www.zacks.com/stock/news/765813/agios-agio-q4-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-765813 Feb 14, 2020 - Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails http://www.zacks.com/stock/news/765605/pharma-stock-roundup-abbv-agn-post-q4-results-another-alzheimers-study-fails?cid=CS-ZC-FT-analyst_blog|stock_roundup-765605 Feb 14, 2020 - AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review http://www.zacks.com/stock/news/765593/bristol-myers-bmy-car-t-cell-therapy-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-765593 Feb 14, 2020 - Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
White House Claims Other Countries Are "Free-Riding" on U.S. Drug Development https://www.fool.com/investing/2020/02/13/white-house-claims-other-countries-are-free-riding.aspx?source=iedfolrf0000001 Feb 13, 2020 - It's gotten worse over the last 15 years.
Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat http://www.zacks.com/stock/news/763990/prothena-prta-q4-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-763990 Feb 13, 2020 - Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now? http://www.zacks.com/stock/news/763466/is-ishares-msci-usa-equal-weighted-etf-eusa-a-strong-etf-right-now?cid=CS-ZC-FT-smart_beta_etf-763466 Feb 13, 2020 - Smart Beta ETF report for EUSA
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study http://www.zacks.com/stock/news/763946/mercks-keytruda-meets-pfs-endpoint-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-763946 Feb 13, 2020 - Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.

Pages: 123456...98

Page 1>